Uric acid levels predict survival in men with amyotrophic lateral sclerosis

Journal of Neurology

Volumn 259, Issue 9, 2012, Pages 1923-1928

  Paganoni, Sabrina ^a   Zhang, May ^a   Zárate, Alejandro Quiroz ^b   Jaffa, Matthew ^a   Yu, Hong ^a   Cudkowicz, Merit E ^a   Wills, Anne Marie ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Amyotrophic lateral sclerosis; Predictor; Survival; Urate; Uric acid

Indexed keywords

RILUZOLE; URIC ACID;

ADULT; ALS FUNCTIONAL RATING SCALE REVISED TOTAL SCORE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASSISTED VENTILATION; BODY MASS; BULBAR PARALYSIS; CONTROLLED STUDY; DELAYED DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FORCED VITAL CAPACITY; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONSET AGE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RATING SCALE; RISK REDUCTION; SEX DIFFERENCE; SPINAL PARALYSIS; SURVIVAL; SURVIVAL TIME; TIME OF DEATH; TRACHEOSTOMY; URIC ACID BLOOD LEVEL;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROPORTIONAL HAZARDS MODELS; SEX CHARACTERISTICS; SURVIVAL ANALYSIS; URIC ACID;

EID: 84867330990     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6440-7     Document Type: Article

References (23)

1. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A (2007) Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166:561-567
2. De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H (2008) Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum 59(11):1549-1554
3. De Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58:797-800
4. Alonso A, Rodriguez LA, Logroscino G, Hernan MA (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69:1696-1700
5. Ascherio A, Le Witt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA, Parkinson Study Group DATATOP Investigators (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66:1460-1468
6. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Parkinson Study Group PRECEPT Investigators, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65:716-723
7. Auinger P, Kieburtz K, McDermott MP (2010) The relationship between uric acid levels and Huntington's disease progression. Mov Disord 25:224-228
8. Euser SM, Hofman A, Westendorp RG, Breteler MM (2009) Serum uric acid and cognitive function and dementia. Brain 132:377-382
9. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS (2009) Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 6:23-28
10. Lee JE, Song SK, Sohn YH, Lee PH (2011) Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord 26:1533-1536
11. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA (2005) Uric acid and oxidative stress. Curr Pharm Des 11:4145-4151
12. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC (2005) Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci USA 102:3483-3488
13. Amaro S, Planas AM, Chamorro A (2008) Uric acid administration in patients with acute stroke: a novel approach to neuroprotection. Expert Rev Neurother 8:259-270
14. Zoccolella S, Simone IL, Capozzo R, Tortelli R, Leo A, D'Errico E, Logroscino G (2011) An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol 258:238-243
15. Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, Tsehori J, Nefussy B, Drory VE (2009) Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci 285:95-99
16. Paganoni S, Deng J, Jaffa M, Cudkowicz ME, Wills AM (2011) Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 44:20-24
17. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, Drachman DB (2006) Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 60:22-31
18. Cudkowicz ME, Shefner JM, Simpson E, Grasso D, Yu H, Zhang H, Shui A, Schoenfeld D, Brown RH, Wieland S, Barber JR, Northeast ALS Consortium (2008) Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 38:837-844
19. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293-299
20. Ganesalingam J, Stahl D, Wijesekera L, Galtrey C, Shaw CE, Leigh PN, Al-Chalabi A (2009) Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS One 4:e7107
21. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, Lepore V, Serlenga L, Logroscino G (2006) SLAP registry (2006) Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a populationbased study. J Neurol Sci 250:45-49
22. Nath SD, Voruganti VS, Arar NH, Thameem F, Lopez-Alvarenga JC, Bauer R, Blangero J, MacCluer JW, Comuzzie AG, Abboud HE (2007) Genome scan for determinants of serum uric acid variability. J Am Soc Nephrol 18:3156-3163
23. Gao X, Curhan G, Forman JP, Ascherio A, Choi HK (2008) Vitamin C intake and serum uric acid concentration in men. J Rheumatol 35:1853-1858